title: Genealogical analysis as a new approach for the investigation of drug intolerance heritability.
abstract: Genealogical analysis has proven a useful method to understand the origins and frequencies of hereditary diseases in many populations. However, this type of analysis has not yet been used for the investigation of drug intolerance among patients suffering from inherited disorders. This study aims to do so, using data from familial hypercholesterolemia (FH) patients receiving high doses of statins. The objective is to measure and compare various genealogical parameters that could shed light on the origins and heritability of muscular intolerance to statins using FH as a model. Analysis was performed on 224 genealogies from 112 FH subjects carrying either the low-density lipoprotein receptor (LDLR) prom_e1 deletion>15 kb (n=28) or c.259T>G (p.Trp87Gly) (n=84) mutations and 112 non-FH controls. Number of ancestors, geographical origins and genetic contribution of founders, inbreeding and kinship coefficients were calculated using the S-Plus-based GENLIB software package. For both mutations, repeated occurrences of the same ancestors are more frequent among the carriers' genealogies than among the controls', but no difference was observed between tolerant and intolerant subjects. Founders who may have introduced both mutations in the population appear with approximately the same frequencies in all genealogies. Kinship coefficients are higher among carriers, with no difference according to statins tolerance. Inbreeding coefficients are slightly lower among >15-kb deletion carriers than among c.259 T>G carriers, but the differences between tolerants and intolerants are not significant. These findings suggest that although muscular intolerance to statins shows a family aggregation, it is not transmitted through the same Mendelian pattern as LDLR mutations.
authors.affiliation: Département des sciences humaines, Université du Québec à Chicoutimi, Chicoutimi, QC, Canada.
authors.forename: Marc
authors.initials: M
authors.lastname: Tremblay
authors.affiliation: Department of Medicine of Université de Montréal, ECOGENE-21 Clinical Research Center and Lipid Clinic, Chicoutimi, QC, Canada.
authors.forename: Tarek
authors.initials: T
authors.lastname: Bouhali
authors.affiliation: Department of Medicine of Université de Montréal, ECOGENE-21 Clinical Research Center and Lipid Clinic, Chicoutimi, QC, Canada.
authors.forename: Daniel
authors.initials: D
authors.lastname: Gaudet
authors.affiliation: Department of Medicine of Université de Montréal, ECOGENE-21 Clinical Research Center and Lipid Clinic, Chicoutimi, QC, Canada.
authors.forename: Diane
authors.initials: D
authors.lastname: Brisson
mesh_terms: D000368:Aged; D005260:Female; D005789:Genealogy and Heraldry; D030342:Genetic Diseases, Inborn / Q000235:genetics*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D006937:Hypercholesterolemia / Q000188:drug therapy / Q000235:genetics*; D008297:Male; D008875:Middle Aged; D009135:Muscular Diseases / Q000139:chemically induced / Q000235:genetics*; D020125:Mutation, Missense; D011792:Quebec; D011973:Receptors, LDL / Q000235:genetics*
chemical_list: D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; C573412:LDLR protein, human; D011973:Receptors, LDL